ARTICLE | Company News
Fate Therapeutics, Boston Children’s Hospital deal
July 27, 2015 7:00 AM UTC
Under a two-year deal, the hospital will assess Fate’s PD-L1 programmed CD34+ cell therapy in preclinical models of autoimmune and inflammatory diseases, including Type I diabetes. Fate will have an ...